Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
The official product label and its RX mirror are one underlying evidence family, not two independent clinical validations. Confirm the current exact product label before prescribing.
DAYPRO 600 mg oral caplets. This selected renal summary is for adult osteoarthritis/rheumatoid arthritis use; pediatric weight-based dosing is not supplied here.
Renal method
Qualitative severe renal impairment / dialysis; the selected dose paragraph does not define a numerical CrCl cutoff.
Source revision
11/2024
Retrieved
2026-10-02
Local review status
Selected renal sections summarized locally. Not a complete monograph or independent clinical approval.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
Before use: Oxaprozin oral caplets (Daypro)
Do not treat 600 mg daily as permission to use an NSAID in advanced kidney disease.
What to reconcile: First establish that use is justified despite the renal warning; then apply only the exact product-label instructions.
Pfizer / DAYPRO prescribing information · DAYPRO 600 mg oral caplets. This selected renal summary is for adult osteoarthritis/rheumatoid arthritis use; pediatric weight-based dosing is not supplied here.
Renal method: Qualitative severe renal impairment / dialysis; the selected dose paragraph does not define a numerical CrCl cutoff. Source date: 11/2024 Retrieved: 2026-10-02
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding
First establish that use is justified despite the renal warning; then apply only the exact product-label instructions.
Dialysis evidence: A dialysis-population initial dose is reported; maintenance requires titration
Selected renal sections summarized locally. Not a complete monograph or independent clinical approval.
Renal guidance and important limits
Limits that apply to these rows
No numerical severe-impairment cutoff is assigned in this summary. Correct hypovolemia and monitor renal function; consider hyperkalemia risk.
Use the lowest effective dose for the shortest necessary duration. Cardiovascular and gastrointestinal boxed warnings remain applicable.
Avoid unless anticipated benefit outweighs worsening-renal-function risk. This warning still applies to the reduced starting dose.
Severe renal impairment or dialysis, when treatment is justified
Start 600 mg orally once daily. Only if symptom relief is inadequate, cautiously increase to 1200 mg with close monitoring.
Read the retained text before reformatting
Renal setting
Source-specific action and limits
Advanced renal disease
Avoid unless anticipated benefit outweighs worsening-renal-function risk. This warning still applies to the reduced starting dose.
Severe renal impairment or dialysis, when treatment is justified
Start 600 mg orally once daily. Only if symptom relief is inadequate, cautiously increase to 1200 mg with close monitoring.
No numerical severe-impairment cutoff is assigned in this summary. Correct hypovolemia and monitor renal function; consider hyperkalemia risk.
Use the lowest effective dose for the shortest necessary duration. Cardiovascular and gastrointestinal boxed warnings remain applicable.
RDM68-oxaprozin-daypro-4eddc1c0d0 · Source locator: Sections 2.5 and 5.6; boxed warning
Source-specific limits
The official product label and its RX mirror are one underlying evidence family, not two independent clinical validations. Confirm the current exact product label before prescribing.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh Renal Dosing Master v6.8. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.